Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

62.34USD
4:00pm EDT
Change (% chg)

$-1.26 (-1.98%)
Prev Close
$63.60
Open
$62.81
Day's High
$62.81
Day's Low
$60.21
Volume
56,325
Avg. Vol
126,206
52-wk High
$99.26
52-wk Low
$19.32

Chart for

About

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical... (more)

Overall

Beta: --
Market Cap(Mil.): $1,988.33
Shares Outstanding(Mil.): 29.68
Dividend: --
Yield (%): --

Financials

  RETA.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -2.06 -- --
ROI: -76.45 1.96 12.83
ROE: -- 1.12 14.95

BRIEF-Reata Pharmaceuticals Posts Q1 Earnings Per Share $0.16

* REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

May 08 2018

BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone

* REATA ANNOUNCES NEW PRECLINICAL DATA DEMONSTRATING THE POTENTIAL OF OMAVELOXOLONE IN THE TREATMENT OF FRIEDREICH’S ATAXIA AND OTHER SEVERE NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:

Apr 24 2018

Earnings vs. Estimates